Evidence map›Paper›PMID 41490046›Full record

ArticlePLoS biology2026

TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia.

Vidhya Maheswari Jawahar, Yi Zeng, Ellen M Armour, Mei Yue, Kathryn Citrano, Anastasiia Lovchykova, Madison M Reeves, Bailey Rawlinson, Michael DeTure, Judith A Dunmore and 15 more

Abstract read
In one paragraph

Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Vidhya Maheswari JawaharDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Yi ZengDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Ellen M ArmourDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Mei YueDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Kathryn CitranoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Anastasiia LovchykovaDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Madison M ReevesDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Bailey RawlinsonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Judith A DunmoreDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Yuping SongDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Sophie K BallDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America.
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
Scott A SmallDepartment of Neurology, Columbia University, New York, New York, United States of America.
Dennis W DicksonNeuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, Florida, United States of America.
Michael E WardNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, United States of America.
Tania F GendronDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Yongjie ZhangDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Mercedes PrudencioDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Aaron D GitlerDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.ORCID https://orcid.org/0000-0003-2959-129X

Funding

Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Expanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6M
Human Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI GITLER, AARON D. · 2021 to 2025
$8.2M
Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteinsR01NS117461 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Tania France Gendron, Yongjie Zhang · 2021 to 2026
$2.9M
Defining modifiers and mechanisms of RAN translationR01AG064690 · NIA · STANFORD UNIVERSITY · PI Aaron D. Gitler, JOSEPH D PUGLISI · 2024 to 2026
$2.3M
Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategiesR35NS137159 · NINDS · STANFORD UNIVERSITY · PI Aaron D. Gitler · 2025 to 2026
$2.3M
Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasR01NS120992 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, PRUDENCIO, MERCEDES · 2024 to 2025
$1.6M
NIA NIH HHS R01 AG064690NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS117461NINDS NIH HHS R01 NS120992NINDS NIH HHS R35 NS097273NINDS NIH HHS R35 NS137159NINDS NIH HHS U54 NS123743
6 · The paper itself

Abstract

TAR DNA-binding protein 43 (TDP-43) dysfunction is a hallmark of several neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease. Although cryptic exon inclusion is a well-characterized consequence of TDP-43 loss of function, emerging evidence reveals broader roles in RNA metabolism, notably in the regulation of alternative polyadenylation (APA) of disease-relevant transcripts. In the present study, we examined 3' untranslated region lengthening events in the brains of individuals with frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), focusing on the functional impact of APA dysregulation. To investigate whether TDP-43-mediated APA events occur in the postmortem brain, we measured the 3' untranslated region length of the retromer component vacuolar protein sorting 35 (VPS35) and the ETS transcription factor (ELK1) in the frontal cortex of a large cohort of FTLD-TDP patients and of healthy controls, and evaluated if these APA events are associated with FTLD-TDP clinical characteristic, markers of TDP-43 pathology [e.g., hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA], or the expression of VPS35 and VPS29 proteins, the latter being essential to the retromer complex. We identified robust 3' untranslated region lengthening of VPS35 and ELK1 in FTLD-TDP, which strongly associated with markers of TDP-43 pathology, and ELK1 APA also associated with an earlier age of disease onset. Functionally, VPS35 APA was associated with reduced VPS35 and VPS29 protein expression, and lower VPS35 levels were associated with increased hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA. Together, these data implicate APA dysregulation as a critical downstream consequence of TDP-43 dysfunction and suggest that TDP-43 loss may contribute to retromer impairment through APA-mediated repression of retromer subunits.

Indexed as

DNA-Binding ProteinsFrontotemporal DementiaPolyadenylationVesicular Transport Proteins3' Untranslated RegionsAgedAged, 80 and overFemaleHumansMaleMiddle Aged3' Untranslated RegionsDNA-Binding ProteinsTARDBP protein, humanVesicular Transport Proteins

Identifiers

PMID41490046
PMCPMC12768243

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.